Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395866873> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2395866873 endingPage "795" @default.
- W2395866873 startingPage "795" @default.
- W2395866873 abstract "In a previous meta-analysis investigating pharmacological treatment options in obsessive-compulsive disorder (OCD) we determined a significant efficacy for the augmentation of serotonin reuptake inhibitors (SRIs) with antipsychotic drugs. Because new relevant double-blind, randomized, placebo-controlled trials (DB-RCTs) evaluating new antipsychotics were conducted, we updated our meta-analysis. We included all DB-RCTs that compared augmentation of SRIs with antipsychotics to placebo augmentation in SRI-resistant OCD. Meta-analytic outcomes were treatment response defined by 35% reduction in Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) total score and mean changes in Y-BOCS total score. Effect sizes were standardized mean differences (SMD) and risk ratios (RR). Fourteen DB-RCTs (n=467) investigating quetiapine (N=5, n=178), risperidone (N=3, n=72), aripiprazole (N=2, n=79),olanzapine (N=2, n=70), haloperidol (N=1, n=34), and paliperidone (N=1, n=34) were incorporated. The pooled antipsychotic augmentation group was significantly superior to the placebo group in terms of response rates (N=14,n=467; RR=1.98, 95% CI: 1.23 to 3.19;p=0.005) and mean change in Y-BOCS total score (N=14, n=465, SMD=-0.6, 95% CI: -0.97 to -0.23; p=0.002). Concerning the individual antipsychotics, aripiprazole and risperidone significantly outperformed placebo in terms of both responder rates and mean Y-BOCS change. Olanzapine, paliperidone, and quetiapine were not significantly different from the control group. There was no significant heterogeneity and no evidence for publication bias. Aripiprazole and risperidone augmentation of SRIs canbe regarded as evidence-based treatment options in treatment-resistant OCD and showed superiority over olanzapine, paliperidone, and quetiapine. About one third of all SRI-resistant OCD subjects responded to augmentation with antipsychotic drugs." @default.
- W2395866873 created "2016-06-24" @default.
- W2395866873 creator A5005289260 @default.
- W2395866873 creator A5023419818 @default.
- W2395866873 creator A5029934619 @default.
- W2395866873 creator A5048960705 @default.
- W2395866873 date "2015-03-01" @default.
- W2395866873 modified "2023-09-25" @default.
- W2395866873 title "Evaluation of the Efficacy of Antipsychotic Drugs in Sri-resistant Obsessive-compulsive Disorder" @default.
- W2395866873 doi "https://doi.org/10.1016/s0924-9338(15)30619-2" @default.
- W2395866873 hasPublicationYear "2015" @default.
- W2395866873 type Work @default.
- W2395866873 sameAs 2395866873 @default.
- W2395866873 citedByCount "1" @default.
- W2395866873 countsByYear W23958668732019 @default.
- W2395866873 crossrefType "journal-article" @default.
- W2395866873 hasAuthorship W2395866873A5005289260 @default.
- W2395866873 hasAuthorship W2395866873A5023419818 @default.
- W2395866873 hasAuthorship W2395866873A5029934619 @default.
- W2395866873 hasAuthorship W2395866873A5048960705 @default.
- W2395866873 hasConcept C118552586 @default.
- W2395866873 hasConcept C126322002 @default.
- W2395866873 hasConcept C142724271 @default.
- W2395866873 hasConcept C15744967 @default.
- W2395866873 hasConcept C168563851 @default.
- W2395866873 hasConcept C204787440 @default.
- W2395866873 hasConcept C27081682 @default.
- W2395866873 hasConcept C2776412080 @default.
- W2395866873 hasConcept C2776619155 @default.
- W2395866873 hasConcept C2777126507 @default.
- W2395866873 hasConcept C2780057945 @default.
- W2395866873 hasConcept C2780211496 @default.
- W2395866873 hasConcept C2780494398 @default.
- W2395866873 hasConcept C2780634440 @default.
- W2395866873 hasConcept C2780948584 @default.
- W2395866873 hasConcept C513476851 @default.
- W2395866873 hasConcept C71924100 @default.
- W2395866873 hasConceptScore W2395866873C118552586 @default.
- W2395866873 hasConceptScore W2395866873C126322002 @default.
- W2395866873 hasConceptScore W2395866873C142724271 @default.
- W2395866873 hasConceptScore W2395866873C15744967 @default.
- W2395866873 hasConceptScore W2395866873C168563851 @default.
- W2395866873 hasConceptScore W2395866873C204787440 @default.
- W2395866873 hasConceptScore W2395866873C27081682 @default.
- W2395866873 hasConceptScore W2395866873C2776412080 @default.
- W2395866873 hasConceptScore W2395866873C2776619155 @default.
- W2395866873 hasConceptScore W2395866873C2777126507 @default.
- W2395866873 hasConceptScore W2395866873C2780057945 @default.
- W2395866873 hasConceptScore W2395866873C2780211496 @default.
- W2395866873 hasConceptScore W2395866873C2780494398 @default.
- W2395866873 hasConceptScore W2395866873C2780634440 @default.
- W2395866873 hasConceptScore W2395866873C2780948584 @default.
- W2395866873 hasConceptScore W2395866873C513476851 @default.
- W2395866873 hasConceptScore W2395866873C71924100 @default.
- W2395866873 hasLocation W23958668731 @default.
- W2395866873 hasOpenAccess W2395866873 @default.
- W2395866873 hasPrimaryLocation W23958668731 @default.
- W2395866873 hasRelatedWork W1843527802 @default.
- W2395866873 hasRelatedWork W1985570731 @default.
- W2395866873 hasRelatedWork W2252986970 @default.
- W2395866873 hasRelatedWork W2349185474 @default.
- W2395866873 hasRelatedWork W2421854174 @default.
- W2395866873 hasRelatedWork W2540269208 @default.
- W2395866873 hasRelatedWork W2735838375 @default.
- W2395866873 hasRelatedWork W2767514304 @default.
- W2395866873 hasRelatedWork W3102273891 @default.
- W2395866873 hasRelatedWork W1978844515 @default.
- W2395866873 hasVolume "30" @default.
- W2395866873 isParatext "false" @default.
- W2395866873 isRetracted "false" @default.
- W2395866873 magId "2395866873" @default.
- W2395866873 workType "article" @default.